For help on how to get the results you want, see our search tips.
2 results
Medicine type
Biosimilar Remove Biosimilar filter
Orphan medicine Remove Orphan medicine filter
Additional monitoring Remove Additional monitoring filter
Medicine
Paediatric investigation plans Remove Paediatric investigation plans filter
Referrals Remove Referrals filter
Categories
Human Remove Human filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Referral safety status
Yes Remove Yes filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
-
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020